

Preparation of chiral isoxazole carbinols via catalytic asymmetric Corey-Bakshi-Shibata reduction

Kevin C. Rider,^{a,b} David J. Burkhart,^{a,c} Chun Li,^{a,d} Andrew R. McKenzie,^{a,e}
Jared K. Nelson,^{a,f} and Nicholas R. Natale^{a,b*}

^a Department of Chemistry, University of Idaho, Moscow ID 83844-2343 ^b Center for Structural and Functional Neuroscience, Department of Biomedical and Pharmaceutical Sciences, The University of Montana, Missoula MT 59812

Current addresses: ^c GSK Biologicals, 553 Old Corvallis Rd., Hamilton MT 59840,

^d Ithaca College, Department of Chemistry, 355 Center for Natural Sciences, Ithaca NY 14850

^e AstraZeneca R&D Boston, 35 Gatehouse Dr., Waltham, MA 0245, ^f PharmAgra Labs, 158 McClean Rd., Brevard, NC 28712

E-mail: nicholas.natale@umontana.edu

Dedicated in Honor of Dr. Bruce E. Maryanoff and Dr. Cynthia A. Maryanoff on the occasion of their outstanding contributions to organic chemistry as industrial chemists

DOI: <http://dx.doi.org/10.3998/ark.5550190.0011.809>

Abstract

A diverse set of isoxazoles, with activity in three different disease categories, was reduced asymmetrically from pro-chiral ketones to chiral alcohols using the Corey-Bakshi-Shibata methodology at the α , β , and γ positions relative to the C-5-methyl of the isoxazole. The experiments described provide an easy route to hydroxylated isoxazoles that represent the common CYP-450 3A4 metabolic site.

Keywords: Asymmetric synthesis, catalysis, isoxazole, oxazaborolidine, reduction

Introduction

Isoxazoles have found continuing application in medicinal chemistry, several examples of which have advanced to general medical practice.¹ As potential new chemical entities advance from *in vitro* screening through *in vivo* study towards clinical trials, pharmacokinetic properties - collectively referred to as ADMET for Absorption, Distribution, Metabolism, Excretion and Toxicity² - become important considerations: half of drug attrition can be attributed to poor ADMET properties. An interesting facet of the biology of isoxazoles is that one significant route

of metabolism and excretion is C-5 methyl hydroxylation,³ mediated by the cytochrome P450 isoform 3A4,⁴ often followed by conjugation to the glucuronide.⁵ The existence of a safe route for drug metabolism is an important design feature for potential investigational new drugs containing the isoxazole. Our own interest in the biological activity of several classes of isoxazoles⁶⁻⁸ required access into isoxazole carbinols in chiral form for metabolic fate experiments.

Our initial attempts used an extension of our previous studies on the lateral metalation and electrophilic quenching of isoxazoles⁹⁻¹⁰ into the realm of asymmetric catalysis.^{11,12} Over fifty attempts employing chiral bis-oxazolines,¹³ Shibasaki's lanthanum BINOL,¹⁴ Jacobsen's salen aluminum catalyst,¹⁵ and Sparteine,¹⁶ in the lateral metalation reaction failed to produce a significant enantio-enrichment of the product.


We sought an alternate route which would provide synthetically useful results, and now report that the use of the Corey-Bakshi-Shibata (CBS)¹⁷ reduction on isoxazolyl ketones produces chiral isoxazolyl carbinols in uniformly excellent chemical yields with high enantio-control in many cases.

Results and Discussion

The racemic alcohols **1a-j** were prepared using lateral metalation as previously described: α -hydroxyls were prepared by lateral metalation followed by quenching with the Davis oxaziridine,¹⁸ β -hydroxyls were prepared by quenching with the appropriate aldehyde,^{10b,c} and the γ -hydroxyl example was prepared by ring opening of styrene.¹⁹ The ketones **2a-j** were then prepared by oxidation using the Dess-Martin Periodinane reagent.²⁰

The reductions illustrated in Scheme 1 were typically carried out at -45°C in dichloromethane, monitored by TLC until consumption of the ketone, and the chemical yields were uniformly very good to excellent. The enantiomeric excess was determined by HPLC-CSP and the results are summarized in Chart 1. The absolute configuration of (S)-**3a** was established by comparison of optical rotation to (R)-**3a** established by single crystal X-ray diffractometry using anomalous scattering techniques on a derived chloro-phenylisoxazolo[3,4-*d*]pyridazinone as previously described.¹² The absolute configuration of (S)-**3j**, produced by reduction with (*R*)-(-)-2-(diphenylhydroxymethyl)-pyrrolidine ((*R*)-diphenyl-prolinol), which was established by its optical rotation by comparison to known (S)-**3j**, established via epoxide ring opening with retention from (*R*)-styrene oxide.¹⁹ The remaining configurations were established by the order of elution via chiral HPLC-CSP. The stereochemical outcome appears to be consistent with the Corey transition state model.¹⁷ High enantioselectivities were observed for aryl-alkyl ketones **3j** (89% *e.e.*), **3g** (97% *e.e.*), **3h** (99% *e.e.*), where the discriminating factor during the reduction is essentially analogous to acetophenone,^{17c} and the isoxazolyl function is removed from the reduction site. The *p*-chlorophenyl compound **3h** produced virtually enantiopure material. As the isoxazolyl function increases in functional complexity and presents potential competing

chelating groups, the *e.e.* is observed to erode slightly as in example **6** (80% *e.e.*). For the case of the dihydropyridine **3i**, two equivalents of borane are necessary to effect conversion to alcohol, and a plethora of potential lone pairs, as well as conformational flexibility, “confuse“ the situation, resulting in significantly lower stereoselectivity (47% *e.e.*). Thus, a complex interplay of both steric and electronic factors affects the selectivity. Steric factors alone do not appear to affect the outcome if the large group is more than one methylene removed from the ketone: in example **3e**, where the local environment at the ketone presents a methyl *versus* a methylene, produced almost no induction, despite the presence of the dirigible-like anthracene-isoxazole moiety nearby.



Scheme 1. Dess-Martin periodinane (DMP), CH₂Cl₂. (b) BH₃.DMS, 10-20 mol.% (*R*)-diphenylprolinol, -45°C, CH₂Cl₂.




Chart 1. Enantioselectivity in the CBS reduction of isoxazoly-ketones at 20 mole % CBS loading, measured by HPLC-CSP using either Chiralpak AD or Chiralcel OJ, 40:1 hexanes: EtOH. The (R)-CBS-oxazaborolidine was used unless otherwise noted.

The standard experiments were conducted at 20 mole % catalyst loading, although the enantiomeric excess was not dramatically affected in the case of **3g** by lowering the amount of chiral oxazaborolidine to 10 mole %: the chemical yield was not affected (93 *versus* 92 % yield), and only a slight change in the *e.e.* was noted (97 to 93% *e.e.*). This was also true for example **3b**, where 10 mole % chiral catalyst produced almost identical yield and stereoselectivity (76 *versus* 74% yield, identical 72% *e.e.*). Unfortunately, for the cases with lower *e.e.*, for example **3b**, raising the catalyst loading from 20 to 80 mole % showed virtually no effect on yield (74 *versus* 73% chemical yield), but the large increase in chiral catalyst produced only a slight increase in *e.e.*, that might be within experimental error (raised only to 75 from 72 % *e.e.*).

In the remaining four examples the isoxazole represents the aryl group, and in the case where the small group is methyl the *e.e.* is lowest **3a**, (43% *e.e.*). In the remaining three cases the *e.e.*'s are higher, **3b-d** (72-82% *e.e.*) which may be consistent with the ability to adopt similar major conformations *vis-a-vis* the keto isoxazoles **2** which led to conformational restriction during the

critical hydride delivery. However, there is another possibility in that these ketones are easily enolizable, as evidenced by the X-ray structure of the enol corresponding to **2d**,²² which we postulated could influence the reaction course. Therefore we examined the reactions for **3d** in more detail. There was a noticeable solvent effect, as dichloromethane (72% *e.e.*) produced slightly higher *e.e.* than THF (63% *e.e.*). In THF we also noticed a pronounced aging effect, that is, over the course of standing the *e.e.* was observed to erode, in one experiment conducted at -45 °C from 83% *e.e.* at 18 hours and incomplete conversion, to 64% *e.e.* at 66 hours. The aging effect was even more pronounced at higher temperature, where the initial 82% *e.e.* at 20 hours eroded to 39% *e.e.* at -20°C over 110 hours. Our explanation for the aging of the *e.e.* for **3d** may be a Meerwein-Ponndorf-Verley reduction / Oppenauer oxidation type disproportionation, which leads to racemization over time.

Conclusions

We have shown that CBS-oxazaborolidine can be used to reduce C5-isoxazolyl-ketones under conditions that optimize chemical yield and enrich enantio-purity. Our results are consistent with Corey's transition state model and show selectivity, as the method gives the corresponding opposite enantiomer from that of the catalyst used [*i.e.*, (*R*)-CBS give (*S*)]. The solvent effects we observed in attrition of % *e.e.* can possibly be explained by the enolizability of the starting ketone corresponding with reaction solvent – THF is poor when compared to methylene chloride – and time, though it appears that a small amount of THF is tolerated as **3b** was separately synthesized using reagent dimethyl sulfide /borane complex in THF and CH₂Cl₂, and the % *e.e.* was unchanged. Temperature had little effect on chemical yield, but a pronounced effect on final enantio-enrichment when THF was used as the reaction solvent, making -45°C the optimal temperature for this series of reactions, as it was easily maintained over the usual 24 hour reaction time.

The results of this study have allowed us to continue our work with isoxazole functionalization of the C-5 position of the ring, such that we are now able to introduce hydroxyl groups in the α -, β - and γ - positions to the isoxazole, that will aid in future metabolic studies of our compounds with CYP-450 3A4 – the predicted isozyme for isoxazole metabolism as based on literature precedent. This methodology not only allows access to the CYP-450 3A4 potential metabolites but the added element of chirality can be explored in both the activity of the hydroxy-isoxazole in its corresponding disease area and bio-availability, thus allowing exploration of the ADMET profile of these compounds. We will report on our progress in due course.

Experimental Section

General. Mass spectra were obtained on a JEOL JMS-AX505 HA. NMR spectra (^1H - and ^{13}C -) were obtained on a Bruker Avance 300 Digital NMR (300 MHz) using SGI-IRIX 6.5. Elemental analyses were performed by Desert Analytics Laboratory, PO Box 41838, Tucson, Arizona 85717. All reactions were performed under argon atmosphere. Tetrahydrofuran was distilled from sodium–benzophenone immediately before use. Dichloromethane was freshly distilled from P_2O_5 before use. The Dess-Martin reagent was synthesized according to literature methods²¹ and stored under argon in a freezer. Radial chromatography was performed on silica gel (Merck 60 A, 230-400mesh). Ethyl 3-(10'-chloro-9'-anthracenyl)-5-methyl-4-isoxazolecarboxylate and ethyl 3-(10'-chloro-9'-anthracenyl)-5-phenylethyl-4-isoxazolecarboxylate were synthesized *via* the routes developed by our laboratory.^{10c,18b} Compound 3f has been characterized in racemic form.^{10c}

General procedure for the Dess-Martin oxidation of isoxazolyl alcohols

To an oven-dried round bottom flask (50mL) was added 2.3g (11.5 mmol) of the isoxazole alcohol and a magnetic stir bar, under a N_2 atmosphere. Freshly distilled dichloromethane (40 mL) was added and the solution stirred until the isoxazole alcohol completely dissolved. Dess-Martin periodinane (4.87g, 1.0 eq.) was added in one portion and the solution stirred for 2-3 hours: the reaction progress was monitored by TLC. After TLC analysis indicated depletion of the starting alcohol, the reaction was concentrated under vacuum and diluted with diethyl ether (100mL). The periodinane by-product which precipitates is then filtered and the ether solution combined with 25 mL saturated NaHCO_3 , and 25 mL of saturated sodium sulfide in a 250 mL flask. The biphasic mixture is stirred vigorously for 15 minutes and then transferred to a separatory funnel. The organic phase is separated, washed with brine (25 mL), dried with anhydrous sodium sulfate, and concentrated. Purity was determined by ^1H -NMR and the compounds purified by column chromatography (Hex: EtOAc) on silica gel if necessary. Final compounds were fully characterized by ^1H NMR, ^{13}C NMR, and elemental analysis or accurate mass determination. Complete characterization has been reported for **2b**, **2g**, **2i** and **2j**.²⁰

Ethyl 5-acetyl-4-(5,5-dimethyl-1,3-dioxan-2-yl)isoxazole 3-carboxylate 2a. Purified by radial chromatography using hexanes: EtOAc (5:1) to afford 53 mg of **2a**, 93% yield. ^1H NMR δ 0.68 (s, 3H), 1.19 (s, 3H), 1.41 (t, 3H, $J=7.1$ Hz), 1.79 (s, 3H), 2.69 (s, 3H), 3.34 (m, 4H), 4.45 (q, 2H, $J=7.1$ Hz). Accurate mass: Calculated for $\text{C}_{15}\text{H}_{22}\text{NO}_6$: 312.1447. Found: 312.1435.

Ethyl 5-butanoyl-3-(10-chloro-9-anthryl)isoxazole-4-carboxylate 2c. Yellow solid from hexane-ethyl acetate (6:1), mp 85.5 °C; ^1H -NMR (CDCl_3): δ (ppm) 0.57 (t, $J=7.1\text{Hz}$, 3H), 1.13 (t, $J=7.3\text{Hz}$, 3H), 1.94 (m, 2H), 3.20 (t, $J=7.1\text{Hz}$, 2H), 3.85 (q, $J=7.1\text{Hz}$, 2H), 7.53 (m, 2H), 7.65 (m, 4H), 8.62 (d, $J=8.4\text{Hz}$, 2H); ^{13}C -NMR (CDCl_3): δ (ppm) 12.95, 13.57, 16.73, 43.25, 61.48, 116.32, 120.30, 125.21, 125.50, 126.86, 127.00, 128.35, 131.19, 131.96, 159.82, 160.57, 166.79, 189.97; MS (EI): m/z 421.20 (M^+ , 100%), 350.10 (13.17%), 322.10 (15.08%), 277.05 (22.31%),

236.95 (12.21%), 214.05 (13.52%), 176.05 (10.96%). Anal. Calcd. for C₂₄H₂₀NO₄Cl: C, 68.33; H, 4.78; N, 3.32. Found: C, 68.19; H, 4.82; N, 3.38%.

Ethyl 3-(10'-chloro-9'-anthracenyl)-5-phenylacetyl-4-isoxazolecarboxylate 2d. Yellow solid from hexane-ethyl acetate (6:1), mp 134-135 °C; ¹H-NMR (CDCl₃): δ(ppm) 0.55 (t, J=7.1Hz, 3H), 3.81 (q, J=7.1Hz, 2H), 4.49 (s, 1H), 7.42 (m, 4H), 7.54 (m, 4H), 7.65 (m, 3H), 8.62 (d, J=8.4Hz, 2H); ¹³C-NMR (CDCl₃): δ (ppm) 12.94, 48.08, 61.47, 116.71, 120.17, 125.19, 125.45, 126.84, 126.99, 127.67, 128.32, 128.92, 129.93, 131.15, 131.74, 131.90, 159.62, 160.51, 166.63, 187.55; MS (EI): *m/z* 469.20 (M⁺, 100%), 350.10 (11.24%), 322.10 (14.49%), 277.05 (36.36%), 214.10 (13.23%), 176.10 (17.76%), 91.05 (15.78%). Anal. Calcd. for C₂₈H₂₀NO₄Cl: C, 71.57; H, 4.29; N, 2.98. Found: C, 70.84; H, 4.39; N, 2.90%.

Ethyl 3-(10-chloro-9-anthracenyl)-5-(2-oxo-2-methyl)isoxazole-4-carboxylate 2e. Yield 98%, m.p. 115-117°C, ¹H NMR (CDCl₃) δ □ 8.6 (d, 2H), 7.69-7.61 (m, 4H), 7.54-7.50(m, 2H), 4.48(s, 2H), 3.7 (q, J = 7.2 Hz, 2H), 2.45(s, 3H), 0.35(t, J = 7.2, 3H); ¹³C NMR □ 173.48, 162.53, 132.04, 129.33, 129.18, 127.61, 126.67, 126.25, 126.15, 125.94, 61.28, 42.84, 31.10, 13.68; MS (EI) *m/z* 69(10.85), 174(10.24), 175(10.97), 176(35.22), 177(9.93), 190(10.11), 201(13.14), 203(13.28), 212(15.42), 213(11.46), 214(36.54), 215(18.69), 216(9.99), 224(10.77), 225(11.11), 226(15.10), 227(19.71), 228(14.60), 237(30.08), 238(11.13), 239(14.28), 243(13.25), 250(14.06), 251(11.65), 253(24.38), 262(15.36), 277(36.96), 278(17.45), 279(19.87), 322(10.41), 373(22.16), 407 (C₂₃H₁₈³⁵CINO₄, 100, M⁺), 408(34.72, (M+1)⁺), 409 (C₂₃H₁₈³⁷CINO₄, 43.14, (M+2)⁺).

Ethyl 3-(10-chloro-9-anthracenyl)-5-(2-oxo-2-phenethyl)isoxazole-4-carboxylate 2f. Yield 95%, m.p. 105-107°C, ¹H NMR(CDCl₃) δ □ 8.53 (d, 2H), 8.03 (d, 2H), 7.64-7.42 (m, 9H), 4.97 (s, 2H), 3.6 (q, J = 7.2 Hz, 2H), 0.23 (t, J = 7.2 Hz, 3H); ¹³C NMR δ □ 192.88, 173.85, 161.74, 160.96, 136.66, 134.82, 132.00, 131.97, 129.77, 129.23, 129.18, 129.11, 127.54, 127.52, 126.69, 125.83, 122.99, 114.10, 61.16, 38.62, 31.10, 30.49, 21.85, 14.99, 13.60; MS (EI) *m/z* 77 (17.74), 105 (63.23), 176 (11.07), 205 (45.29), 220 (15.52), 237 (19.05), 253 (11.79), 469 (C₂₈H₂₀³⁵CINO₄, 100, M⁺), 470 (34.36, (M+1)⁺), 471 (C₂₈H₂₀³⁷CINO₄, 40.26, (M+2)⁺).

Ethyl 5-[2-(4-chlorophenyl)-2-oxo-ethyl]-4-(2,5,5-trimethyl-1,3-dioxan-2-yl)-isoxazole-3-carboxylate 2h. Yield 89%, colorless solid, m.p. = 53-54 °C ¹H-NMR δ 0.66 (s, 3H), 1.42 (s, 3H), 1.38 (t, J = 4.2 Hz, 3H), 1.66 (s, 3H), 3.34 (m, 4H), 4.42 (q, J = 4.2 Hz, 2H), 4.52 (s, 2H), 7.48 (d, J = 5.1 Hz, 2H) 7.92 (d, J = 5.1 Hz, 2H); ¹³C-NMR 14.4, 22.3, 22.8, 29.9, 30.3, 36.4, 62.9, 72.2, 96.7, 117.3, 128.8, 129.3, 134.3, 136.3, 156.7, 161.9, 164.7, 193.0; Formula weight for C₂₁H₂₄O₆NCl, Calculated 421.13: Accurate mass was done for the M-15 peak 406. The intensity of the molecular ion peak at *m/z* 421 was too low for accurate mass measurement at 5000 resolution. Calculated for C₂₀H₂₁NO₆Cl 406.1057; Found 406.1061.

General procedure for the asymmetric reduction of isoxazolyl aryl ketones

To an oven dried round- bottomed flask and magnetic stir bar was added 2 mL dry CH₂Cl₂, and 0.154 mL of (R)-2-methyl-CBS-oxazaborolidine (1M in toluene), followed quickly by 0.385 mL dimethyl sulfide borane (2M in THF or CH₂Cl₂). The reaction was quickly cooled to -45 °C under a passive Ar atmosphere. Isoxazole ketone (0.3g, 0.77 mmol) was dissolved in 1mL dry CH₂Cl₂ in a separate round bottom flask. The ketone solution was slowly added to the borane solution over a period of 30 minutes. The reaction was maintained at -45 °C with stirring and allowed to react until completion (~24 hours), as determined by TLC. The reaction was quenched by the addition of 5 mL MeOH and concentrated. Purification by column chromatography (Hex: EtOAc) gave the chiral alcohols in pure form. Enantiomeric excess was determined by CSP HPLC using a Chiralcel OJ or AS column (Hex: EtOH, 40:1).

For compounds **3c-3f**, reduction progress was monitored by HPLC, using a Chiralpak AD column and hexane-EtOH (40:1 or 12:1) as the eluting solvent, $\lambda=254\text{nm}$. The % *e.e.* was calculated based on the ratio of the enantiomers. See Chart 1 for the HPLC-CSP ratios.

Synthesis of ethyl 5-[1-hydroxyethyl]-4-(2,5,5-trimethyl-1,3-dioxan-2-yl)isoxazole-3-carboxylate (S)-3a.

An oven- dried round bottomed flask (25 mL) was charged with 8 mL freshly distilled CH₂Cl₂, and a magnetic stir bar at room temperature under an argon atmosphere with a passive flow setup. (R)-2-Methyl-CBS-oxazaborolidine (0.2 equiv., 0.037 mmol, 1.0 M in toluene, 0.037 mL) was added to the flask *via* a gas-tight syringe, followed by addition of borane dimethyl sulfide (1.1 equivalents, 0.205 mmol, 1.0 M in CH₂Cl₂, 0.205 mL) *via* a gas-tight syringe. This catalyst solution was then immediately cooled to -40°C in a dry ice/acetonitrile bath. The ketone (0.186 mmol, 58 mg) was taken up in about 1 mL of CH₂Cl₂, and transferred to the catalyst solution dropwise over 1 hr. The solution was allowed to stir at -40° C for 8-10 hrs, and warmed over 1 hr. Spectroscopic data were identical with those of racemic **3a**.¹² HPLC separation on a chiral stationary phase (Chiralcel AS column, 254 nm detector, 1 ml/min, 30:1 hexanes: EtOH) showed that the product had a 43% enantiomeric excess.

Ethyl 5-[hydroxy-2-phenyl-ethyl]-4-(2,5,5-trimethyl-1,3-dioxan-2-yl)isoxazole-3-carboxylate 3b. Colorless oil, $[\alpha]_{\text{D}}^{25} = +49.0^\circ$, $[c = 1.0, \text{CH}_2\text{Cl}_2]$ ¹H-NMR 0.55 (s, 3H), 1.05 (s, 3H), 1.33 (t, 3H), 3.09 (d, *J*=11Hz, 2H), 3.20 (d, *J* = 11Hz, 2H), 4.33 (q, 2H), 5.09 (t, 1H), 7.08-7.24 (m, 5H); ¹³C-NMR 14.4, 22.2, 22.7, 29.7, 30.1, 42.5, 63.0, 67.9, 72.2, 72.3, 96.7, 116.3, 127.5, 129.1, 129.9, 136.6, 156.6, 161.8, 170.0.

Ethyl 3-(10-chloro-9-anthryl)-5-[1-hydroxybutyl]isoxazole-4-carboxylate 3c. A pale yellow solid, crystallized from hexanes-ethyl acetate (10:1), mp 90-92 °C; ¹H-NMR (CDCl₃): δ (ppm) 0.17 (t, *J*=7.1Hz, 3H), 1.11 (t, *J* = 7.3Hz, 3H), 1.65 (m, 2H), 2.11 (m, 2H), 3.66 (q, *J* = 7.1Hz, 2H), 4.79 (d, *J* = 9.7Hz, 1H), 5.25 (q, *J* = 6.0Hz, 1H), 7.52 (m, 2H), 7.64 (m, 2H), 8.62 (d, *J* = 8.9Hz, 2H); ¹³C-NMR (CDCl₃): δ (ppm) 12.42, 13.75, 18.68, 37.51, 61.04, 67.83, 125.05, 125.09, 125.61, 125.70, 126.73, 128.30, 135.50, 182.03; MS (EI): *m/z* 423.45 (M⁺, 100%), 277.15 (22.34%), 237.10 (18.44%), 214.15 (14.61%), 176.15 (13.71%). Calcd. for C₂₄H₂₂NO₄Cl: C, 68.00; H, 5.23; N, 3.30. Found: C, 68.27; H, 5.44; N, 3.24%.

Ethyl 3-(10-chloro-9-anthryl)-5-[1-hydroxy-2-phenyl-ethyl]isoxazole-4-carboxylate 3d. Yellow flakes from hexanes-ethyl acetate (6:1), mp 123-124 °C; ¹H- NMR (CDCl₃): δ 0.14 (t, 3H, *J* = 14.0Hz), 3.44 (d, 2H, *J* = 6.5Hz), 3.58 (dq, 2H, *J* = 14.0, 2.1Hz), 4.97 (d, 1H, *J* = 8.5), 5.57 (dd, 1H, *J*=6.5, 8.5Hz), 7.32 (m, 3H), 7.38 (m, 2H), 7.50 (ddd, 2H, *J*=10, 5.6, 1.4Hz), 7.57 (ddd, 2H, *J* = 9, 1.25, 0.6), 7.62 (ddd, 2H, *J* = 10, 5.6, 1.4Hz), 8.60ppm (ddd, 2H, *J* = 8.9, 1.25, 0.6Hz); ¹³C NMR (CDCl₃): δ 12.52, 42.41, 61.11, 69.17, 112.05, 122.02, 125.13, 125.17, 125.76, 125.78, 126.73, 126.81, 126.85, 127.17, 128.34, 128.36, 128.62, 129.70, 129.71, 131.18, 131.22, 131.27, 135.98, 160.12, 162.45, 180.01 ppm; MS: *m/z* 471.16 (M⁺), 380.15 (M⁺-PhCH₂), 306.05 (M⁺-PhCH₂-COOC₂H₅), 278.05, 176.10, 91.05. Calcd. for C₂₈H₂₂NO₄Cl: C, 71.26; H, 4.70; N, 2.97. Found: C, 71.33; H, 4.52; N, 2.99%.

Ethyl 3-(10-chloro-9-anthryl)-5-[2-hydroxypropyl]isoxazole-4-carboxylate 3e. Yield 64%. [α]_D²⁰₅₈₉ 0.000° (*c* = 0.79, CH₂Cl₂); m.p. 114.5-116°C, ¹H NMR (CDCl₃) δ □8.6 (d, 2H), 7.65-7.58 (m, 4H), 7.50-7.45 (3m, 2H), 4.47(m, 1H), 3.67 (q, *J* = 7.2 Hz, 2H), 3.51-3.48 (dd, 2H), 2.59 (d, 1H), 1.44 (d, 3H), 0.25 (t, *J* = 7.2 Hz, 3H); ¹³C- NMR, δ □177.94, 162.77, 160.90, 132.04, 132.02, 131.98, 129.61, 129.34, 129.18, 127.61, 127.56, 127.28, 126.67, 126.66, 126.24, 126.14, 125.94, 123.29, 113.32, 67.49, 61.35, 61.23, 37.65, 24.54, 24.41, 13.6, 13.48; MS (EI) *m/z* 176(17.42), 214 (15.37), 227 (11.02), 237 (17.75), 253 (11.97), 277 (29.08), 278 (18.55), 279 (12.86), 375 (30.25), 408 (C₂₃H₁₉³⁵ClNO₄, 100 (M-1)⁺), 410 (C₂₃H₁₉³⁷ClNO₄, 46.54 (M+1)⁺), 411 (C₂₃H₂₀³⁷ClNO₄, 62.25 (M+2)⁺).

Ethyl 3-(10-chloro-9-anthryl)-5-[2-hydroxy-2-phenyl-ethyl]isoxazole-4-carboxylate 3f. Yield 79%, [α]_D²⁰₅₈₉ +0.2465° (*c* = 0.0155, EtOH); m.p. 119-121°C, ¹H- NMR (CDCl₃) δ □8.6 (d, 2H), 7.63-7.28 (m, 6H), 5.45-5.39 (m, 1H), 3.88-3.73 (dd, 2H), 3.67 (q, *J* = 7.1 Hz, 2H), 2.95 (d, 1H), 0.31 (t, *J* = 7.1 Hz 3H); ¹³C- NMR δ □176.25, 161.10, 159.98, 142.74, □131.14, 131.09, 128.69, 128.297, 128.291, 128.20, 126.74, 126.70, 126.65, 126.56, 125.84, 125.82, 125.67, 125.06, 122.36, 112.65, 72.54, 60.48, 37.08, 12.78. MS (EI) *m/z* 77 (13.45), 79 (14.72), 105 (19.34), 163 (10.69), 176 (14.33), 214 (12.65), 277 (23.69), 319 (17.48), 365 (44.89), 471 (100, M⁺), 472 (35.78, (M+1)⁺), 473(37.49(M+2)⁺). Calcd. for C₂₈H₂₂ClNO₄: C, 71.26; H, 4.70; N, 2.97. Found: C, 71.08; H, 4.74; N, 2.84%.

Ethyl 5-[2-hydroxy-2-phenyl-ethyl]-4-(2,5,5-trimethyl-1,3-dioxan-2-yl)isoxazole-3-carboxylate 3g. Yield 91%, yellowish oil, [α]_D²⁵ = +6.9°, [*c* = 1.0, CH₂Cl₂] ¹H-NMR δ 0.60 (s, 3H), 1.15 (s, 3H), 1.35 (t, *J* = 7.18 Hz, 3H), 1.46 (s, 3H), 2.62 d, *J* = 3.59Hz, 1H), 3.12 - 3.40 (m, 6H), 4.36 (q, *J* = 7.18 Hz, 2H), 5.21 (m, 1H), 7.25 -7.35 (m, 5H). ¹³C-NMR δ 13.8, 21.7, 22.3, 29.4, 29.6, 35.9, 62.4, 71.6, 71.8, 96.0, 115.3, 125.5, 128.0, 128.5, 143.0, 156.2, 161.5, 167.6. Calcd for C₂₁H₂₇NO₆: C, 64.77; H, 6.99; N, 3.60. Found: C, 64.47; H, 6.98; N, 3.42%.

Ethyl 5-[2-(4-chlorophenyl)-2-hydroxy-ethyl]-4-(2,5,5-trimethyl-1,3-dioxan-2-yl)-isoxazole-3-carboxylate 3h. Yield 83%, colorless solid, mp. 86 - 88 °C, [α]_D²⁵ = +13.7°; ¹H-NMR δ 0.63 (s, 3H), 1.16 (s, 3H), 1.37 (t, *J* = 7.18 Hz, 3H), 1.54 (s, 3H), 2.36 (d, *J* = 3.59 Hz, 1H), 3.14 - 3.18 (m, 6H), 4.39 (q, *J* = 7.18 Hz, 2H), 5.22 (m, 1H), 7.32 (s, 4H). ¹³C-NMR δ 14.0, 21.9, 22.47, 29.5, 29.8, 36.0, 62.6, 71.5, 71.7, 96.2, 115.8, 127.0, 128.9, 133.9, 141.5, 156.5, 161.7,

167.3. EIMS m/z : 408 $[(M-15)^+]$, 197. Calcd for $C_{21}H_{26}NO_6Cl$: C, 59.50; H, 6.18; N, 3.30. Found: C, 59.56; H, 6.14; N, 3.22%.

Diethyl 4-[5-[2-hydroxy-2-phenyl-ethyl]-3-methyl-isoxazol-4-yl]-1,4-dihydropyridine-3,5-dicarboxylate 3i. Alcohol **3i** was prepared in a similar manner to the general procedure described above, except that 2 eq. of borane-dimethyl sulfide, and the (*S*)-CBS-oxazaborolidine were used. Spectroscopic characteristics of **3i** were identical to those for the product of the racemic synthesis,²⁰ with the exception of the optical rotation ($[\alpha]_D^{20}$ -21.8 (*c* 0.11)). HPLC-CSP parameters: 20:1 hexanes: *iso*-propanol, 10 μ L injection, Chiralpak AD column. 47% *e.e.*

3-[4-(4,4-Dimethyl-5H-oxazol-2-yl)-3-methyl-isoxazol-5-yl]-1-phenyl-propan-1-ol 3j. The alcohol (*S*)-**3j** was prepared in a similar manner by the general procedure described above, in 82% yield. Spectroscopic characteristics of (*S*)-**3j** were identical to the racemate;¹⁹ colorless solid, mp. 86-88 °C, with the exception of the optical rotation $[\alpha]_D^{25} = +3.6^\circ$. HPLC elution parameters: 254 nm on a Chiralcel OJ analytical column, 40:1 hexanes: EtOH, 1 mL/min. 89% *e.e.*

Acknowledgements

NRN thanks the National Institutes of Neurological Disease and Stroke for Grants NS38444 and P20RR015583. DJB, JKN, CL and KCR, acknowledge the Malcolm and Carol Renfrew Scholarship Endowment, University of Idaho. CL and KCR also thank P20RR16454. KCR acknowledges P30 NS055022.

References

1. Pevarello, P.; Amici, R.; Brasca, M. G.; Villa, M.; Varasi, M. *Targets Heterocycl. Syst.* **1999**, *3*, 301.
2. (a) Kennedy, T. *Drug Discovery Today* **1997**, *2*, 436. (b) Hudelson, M. G.; Ketkar, N. S.; Holder, L. B.; Carlson, T. J.; Peng, C.-C.; Waldher, B. J.; Jones, J. P. *J. Med. Chem.* **2008**, *51*, 648.
3. Thijssen, H. H. W. *J. Chromatogr.* **1980**, *183*, 339. (b) Murai, Y.; Nakagawa, T.; Yamaoka, K.; Uno, T. *Chem. Pharm. Bull.* **1981**, *29*, 3290.
4. Lakehal, F.; Dansette, P. M.; Becquemont, L.; Lasnier, E.; Delelo, R.; Ballardur, P.; Poupon, R.; Beaune, P. H.; Housset, C. *Chem. Res. Toxicol.* **2001**, *14*, 694.
5. Zhang, J. Y.; Yuan, J. J.; Wang, Y.-F.; Bible, Jr., R. H.; Breau, A. P. *Drug Metab. Dispos.* **2003**, *31*, 491.
6. Zamponi, G.; Stotz, S. C.; Staples, R. J.; Rogers, T. A.; Nelson, J. K.; Hulubei, V.; Blumenfeld, A.; Natale, N. R. *J. Med. Chem.* **2003**, *46*, 87.

7. Han, X.; Li, C.; Mosher, M. D.; Rider, K. C.; Zhou, P.; Crawford, R. L., Fusco, W.; Paszczynski, A.; Natale, N. R. *Bioorg. Med. Chem.* **2009**, *17*, 1671.
8. Patel, S. A.; Rajale, T.; O'Brien, E.; Burkhardt, D. J.; Nelson, J. K.; Twamley, B.; Blumenfeld, A.; Szabon-Watola, M. I.; Gerdes, J. M.; Bridges, R. J.; Natale, N. R. *Bioorg. Med. Chem.* **2010**, *18*, 202.
9. Natale, N. R.; Mirzaei, Y. R. *Org. Prep. Proced., Int.* **1993**, *25*, 515.
10. (a) Natale, N. R.; Rogers, M. E.; Staples, R.; Triggler, D. J.; Rutledge, A. *J. Med. Chem.* **1999**, *42*, 3087. (b) Burkhardt, D. J.; Zhou, P.; Blumenfeld, A.; Twamley, B.; Natale, N. R. *Tetrahedron* **2001**, *57*, 8039. (c) Han, X.; Li, C.; Rider, K. C.; Blumenfeld, A.; Twamley, B.; Natale, N. R. *Tetrahedron Lett.* **2002**, *43*, 7673.
11. Burkhardt, D. J.; McKenzie, A. R.; Nelson, J. K.; Myers, K. I.; Zhao, X.; Magnusson, K. R.; Natale, N. R. *Org. Lett.* **2004**, *6*, 1285.
12. Nelson, J. K.; Twamley, B.; Villalobos, T. J.; Natale, N. R. *Tetrahedron Lett.* **2008**, *49*, 5957.
13. Johnson, J. S.; Evans, D. A. *Acc. Chem. Res.* **2000**, *33*, 325.
14. Kim, Y. S.; Matsunaga, S.; Das, J.; Sekine, A.; Ohshima, T.; Shibasaki, M. *J. Am. Chem. Soc.* **2000**, *122*, 6506.
15. Sigman, M.; Jacobsen, E. *J. Am. Chem. Soc.* **1998**, *120*, 5315.
16. Hoppe, D.; Hintze, F.; Tebben, P. *Angew. Chem. Int. Ed. Engl.* **1990**, *29*, 1422.
17. (a) Corey, E. J.; Bakshi, R. K.; Shibata, S. *J. Am. Chem. Soc.* **1987**, *109*, 5551. (b) Corey, E. J.; Bakshi, R. K.; Shibata, S. Chen, C.; Singh, V. K. *J. Am. Chem. Soc.* **1987**, *109*, 7925. (c) Mathre, D. J.; Thompson, A. S.; Douglas, A. W.; Hoogsteen, K.; Carroll, J. D.; Corley, E. G.; Grabowski, E. J. *J. Org. Chem.* **1993**, *58*, 2880.
18. (a) Davis, F. A. *J. Org. Chem.* **2006**, *71*, 8993. (b) Li, C.; Twamley, B.; Natale, N. R. *J. Heterocycl. Chem.* **2008**, *45*, 259.
19. Nelson, J. K.; Burns, C. T.; Smith, M. P.; Twamley, B.; Natale, N. R. *Tetrahedron Lett.* **2008**, *49*, 3078.
20. Nelson, J. K.; Burkhardt, D. J.; McKenzie, A.; and Natale, N. R. *Synlett* **2003**, 2213.
21. Dess, D. B.; Martin, J. C. *J. Am. Chem. Soc.* **1991**, *113*, 7277.
22. Li, C.; Twamley, B.; Natale, N. R. *Acta Cryst E.* **2006**, *E62*, o854.